Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice-Reference-Cited by-同舟云学术

Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice

Published:2022-10-05 Issue:12 Volume:6 Page:3363-3378
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Jiang Jie¹²,Ma Yuandi²³,Liu Yameng²,Lu Dasheng⁴,Gao Xiaoxia⁴,Krausz Kristopher W.⁴,Desai Dhimant⁵,Amin Shantu G.⁵,Patterson Andrew D.⁶,Gonzalez Frank J.⁴^ORCID,Xie Cen¹²³⁴^ORCID

Affiliation:

1. School of Chinese Materia Medica Nanjing University of Chinese Medicine Nanjing China

2. State Key Laboratory of Drug Research Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai China

3. University of Chinese Academy of Sciences Beijing China

4. Department of Pharmacology, College of Medicine The Pennsylvania State University Hershey Pennsylvania USA

5. Laboratory of Metabolism, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland USA

6. Department of Veterinary and Biomedical Sciences and the Center for Molecular Toxicology and Carcinogenesis The Pennsylvania State University University Park Pennsylvania USA

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.2099

Reference50 articles.

1. Non-alcoholic fatty liver disease

2. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis